مواقع ذات صلة
الخط الساخن للخدمات الصحية للنازحين اللبنانيين 1787   
الخط الساخن لدخول المرضى الى المستشفيات 01/832700   
التسجيل لأخذ لقاح الكورونا covax.moph.gov.lb   
الخط الساخن لوزارة الصحّة العامة 1214   
هل أنت مستخدم جديد؟ قم بالتسجيل الآن
 
دعنا نساعدك
للوصول إلى هدفك.

الدراسة الإستقصائية للمستشفيات الوطنية

Process
  • All hospitals that are contracted to the MOPH for treatment of MOPH patients in 2001will be included in the First National Hospital Survey and the main purpose is to assess all contracted hospitals against the Basic and Accreditation standards, for bench marking purposes.
  • The First National Hospital Survey will be undertaken by the OPCV Project Team under the supervision of the Ministry of Public Health (MOPH) and the Health Sector Rehabilitation Project (HSRP). The Project is financed by the World Bank.
 
Resources
  • The attached forms cover all acute hospital Departments/ Services for Basic and Accreditation standards.
  • The forms should be considered in conjunction with the relevant section of the (a) Hospital Accreditation Manual, and (b) Guidelines. Both these publications are included in the kit.
  • The forms will be used by the visiting Hospital Survey Team to assess each Department/Service of your hospital against the standards.
  • Your hospital may utilise these forms in your preparation for the survey, by photocopying as many as required for self-assessment purposes. However, in the First National Hospital Survey your self-assessment is not included as a part of the official result.
 
Survey
  • A schedule of visits by the Survey Teams is currently being compiled. It is vitally important that once the survey dates are arranged that your hospital does not alter the dates. There are some 134 hospitals involved in the survey that will take place over a 12 month period. Any hospitals reneging on the survey dates without very advanced negotiation will either go to the back of the queue or be relegated from the survey altogether. Your cooperation in regard to the scheduling is crucial to the success of the exercise.
  • For the majority of hospital surveys there will be three surveyors per team, consisting of a general hospital Administrator, a Nurse with clinical and administrative experience, and a Physician with clinical and administrative experience. There will be an extra clinical team member for hospitals over 150 beds in total.
  • For some surveys there will be an observer with the team. This will be a person from either the MOPH or the HSRP. The observer will be undergoing training as a surveyor through the OPCV so that skills can be transferred for future surveys in Lebanon. The observer will not have any executive, advisory or reporting responsibilities during his/her training period with OPCV. All aspects of confidentiality in regard to individual hospital information and results will be respected.
  • The survey team will be on site at the hospital for a varying number of days depending on hospital size in terms of total bed numbers as per official MOPH lists:
 
Hospital size On site survey days
49 beds or less One day (1)
50-99 beds Two days (2)
100-149 beds Two days (2)
150 + beds Three Days (3)
 
 
Scoring
The scoring system to be used for surveys will be as follows:
Basic standards Yes: One point
No: Zero points
Not Applicable: Excluded from calculation
Accreditation standards Yes: One point
No: Zero points
Needs improvement: 0.5 points
Not applicable: Excluded from calculation
 
  • Needs improvement.This category has been developed for the Accreditation standards so that the survey team can allot some credit where the hospital is making demonstrated progress on a particular standard. The category is not used for the Basic standards because these are lower level standards that are expected to be fully implemented
  • The Survey Team will calculate the Department/ Service results, and the overall result and advise the MOPH and your hospital at the completion of the First National Hospital Survey. All hospitals will be measured against both the Basic and the Accreditation standards
 
Results
  • The overall percentage required for the various assessments are:
% Basic % Accreditation Result Acronym
85% Basic Standards  65% + Accreditation Standards Full Accreditation Status  BFA
65% - 84% Basic Standards 65% + Accreditation Standards Partial Accreditation Status  BPA
65% + Basic Standards < 65% Accreditation Standards No Accreditation Award but passed Basic  BNA
50% - 64% Basic Standards < 65% Accreditation Standards No Accreditation award, Partial pass on Basic  PB
< 50% Basic Standards < 65% Accreditation Standards No Accreditation Award and Failed on Basic Standards NB
 
  • After the on site visit the OPCV Team will be involved in writing up the survey in the OPCV office. A detailed survey assessment report will be completed and Forworded to the MOPH and your Hospital.
  • During the First National Hospital Survey the opportunity will also be taken by the OPCV Team to recommend any changes to the Hospital Accreditation Manual and/or the processes adopted for surveys.
  • Beyond that there will be an interim period in which hospitals can prepare for actual Accreditation Assessment, based on the Survey results.
 
Further Contact
Please contact the OPCV Team Leader or the HSRP if you have any comments or queries about this Accreditation Survey Kit:
  • OPCV: Telephone 1 747 263/64
  • HSRP: Telephone 1 616 601 Mr. Roy Wakim
 
    3
    ...
التصنيف العلاجي الاسم أساسي / جنيسي التركيبة العلمية العيار الشكل الصيدلاني سعر المبيع من العموم
N05AX16 REXULTI B Brexpiprazole - 2mg 2mg Tablet, film coated 13,433,051 L.L
N05AX16 REXULTI B Brexpiprazole - 1mg 1mg Tablet, film coated 13,433,051 L.L
C09AA02 RENITEC B Enalapril maleate - 20mg 20mg Tablet 405,840 L.L
J01FA02 ROVAMYCINE B Spiramycin - 3MIU 3MIU Tablet, film coated 649,076 L.L
J01FA02 ROVAMYCINE B Spiramycin - 1.5MIU 1.5MIU Tablet, film coated 256,674 L.L
V03AE02 RENVELA B Sevelamer - 800mg 800mg Tablet, film coated 8,386,876 L.L
D06BX01 ROZEX B Metronidazole - 0.75g/100g 0.75% Gel 584,571 L.L
J06BB01 RHOPHYLAC 300 BioHuman Human anti-D (rh) immunoglobulin - 300mcg/2ml 300mcg/2ml Injectable solution 5,939,784 L.L
J06BB01 RHESONATIV BioHuman Human anti-D (rh) immunoglobulin - 625IU/ml 625IU/ml Injectable solution 12,281,758 L.L
J06BB05 RABISHIELD-100 (RABIES HUMAN MONOCLONAL ANTIBODY rDNA) BioHuman Rabies, Human IgG1 Monoclonal Antibody - 100IU/2.5ml 100IU/2.5ml 8,455,824 L.L
L03AB07 RECIGEN 44 BioTech Interferon beta-1a - 44mcg/0.5ml 44mcg/0.5ml Injectable solution L.L
L03AB07 REBIF BioTech Interferon beta-1a - 44mcg/0.5ml 12MIU Injectable solution 79,337,698 L.L
L03AB07 RECIGEN 44 BioTech Interferon beta-1a - 44mcg/0.5ml 44mcg/0.5ml Injectable solution 15,147,973 L.L
B02BD02 RECOFACT VIII BioTech Moroctocog alfa - 500IU 500IU Injectable powder for solution+diluent 12,049,005 L.L
L01FA01 RITUXIREL BioTech Rituximab - 100mg 100mg/10ml Injectable concentrated solution L.L
L01FA01 RITUXIREL BioTech Rituximab - 500mg 500mg/10ml Injectable concentrated solution L.L
B02BD04 REFIXIA BioTech Nonacog beta pegol (factor IX) - 500IU 500IU Injectable powder for solution+solvent 76,080,435 L.L
B02BD04 REFIXIA BioTech Nonacog beta pegol (factor IX) - 1000IU 1000IU Injectable powder for solution+solvent 143,279,414 L.L
L03AB07 REBIF BioTech Interferon beta-1a - 44mcg/0.5ml 12MIU Injectable solution L.L
B02BD04 REFIXIA BioTech Nonacog beta pegol (factor IX) - 2000IU 2000IU Injectable powder for solution+solvent 286,711,575 L.L
J07BG01 RABIVAX-S (RABIES VACCINE INACTIVATED) BioTech Freeze dried inactivated purified rabies antigen (Pitman Moore PM3218 as virus strain) - Injectable freeze dried material 1,552,138 L.L
J07BH01 ROTASIIL, ROTAVIRUS VACCINE, LIVE ATTENUATED (ORAL FREEZE-DRIED) BioTech Rotavirus bovine-human , live attenuated - Suspension 2,822,069 L.L
J07BH01 ROTASIIL, ROTAVIRUS VACCINE, LIVE ATTENUATED (ORAL LIQUID) BioTech Rotavirus bovine-human , live attenuated - Liquid 2,822,069 L.L
B02BD08 RECOFACT VII BioTech Eptacog alfa (activated) recombinant - 1.2mg 1.2mg Injectable powder for solution+diluent 47,533,131 L.L
L01FA01 RITUXIREL BioTech Rituximab - 100mg 100mg/10ml Injectable concentrated solution 11,708,063 L.L
L01FA01 RIXATHON BioTech Rituximab - 100mg/10ml 100mg/10ml Injectable concentrate for solution 27,354,833 L.L
L01FA01 RUXIENCE BioTech Rituximab - 100mg/10ml 100mg/10ml Injectable concentrate for solution 13,157,756 L.L
L01FA01 RITUXIREL BioTech Rituximab - 500mg 500mg/50ml Injectable concentrated solution 45,258,360 L.L
L01FA01 RIXATHON BioTech Rituximab - 500mg/50ml 500mg/50ml Injectable concentrate for solution 64,401,569 L.L
L01FA01 RIXATHON BioTech Rituximab - 500mg/50ml 500mg/50ml Injectable concentrate for solution 111,983,163 L.L
    3
    ...
Sitemap
حقوق الطبع والنشر محفوظة ل وزارة الصحة العامة ©2025